Veristat Expands Its San Francisco Bay Area Operations

HOLLISTON, Mass.--Veristat, a full service Clinical Research Organization (CRO), announced today that it has opened a new office in San Bruno, California. Located in the heart of the San Francisco Bay Area life sciences community, the office will house Veristat's West Coast operations, and will provide a full range of clinical services to clients developing therapies in all areas of biotechnology, pharmaceuticals, diagnostics and medical devices.

"Given the elevated activity and success of West Coast life sciences companies, opening an office to domicile and expand our local team in the Bay Area is the next logical step for Veristat." stated Patrick Flanagan, Chief Executive Officer of Veristat. "We have a strong team and a robust client base in the Bay Area. Our new office will allow our team to collaborate more frequently and effectively with our West Coast clients."

"Veristat has been an invaluable partner to Jazz Pharmaceuticals supporting an important NDA submission this year as we expand our R&D initiatives. We congratulate them on their expansion in the Bay Area," commented Charles LaPree, Senior Vice President, Global Head of Regulatory Affairs of Jazz Pharmaceuticals.

The Veristat San Bruno office is currently home to Clinical Operations, Biostatistics, Data Management and Business Development/Account Management. In addition to this new Bay Area office, Veristat has additional offices in Cambridge, MA and Montreal, Canada, and just recently announced the upcoming move of its Corporate Headquarters to Southborough, MA.

About Veristat

Veristat, LLC is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat's unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information, please visit


Gillian Dellacioppa, 508-306-6336
Marketing Director
[email protected]


Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.